Seres Therapeutics, INC Form 4 insider transactions

Director Richard N. Kender acquired stock options for 60,000 shares of Seres Therapeutics at an exercise price of $0.76 on April 4, 2024.

Director Paul Biondi acquired 60,000 stock options in Seres Therapeutics, Inc. on April 4, 2024.

Director Claire Fraser acquired stock options for 60,000 shares of Seres Therapeutics common stock on April 4, 2024.

Director Dere Willard H. acquired 60,000 stock options in Seres Therapeutics, Inc. on April 4, 2024.

Director Dennis A. Ausiello acquired stock options for 60,000 shares of Seres Therapeutics common stock on April 4, 2024.

Director Stephen Berenson acquired stock options in Seres Therapeutics, Inc. on April 4, 2024.

Marella Thorell, EVP and CFO of Seres Therapeutics, acquired 700,000 stock options on March 25, 2024, according to a Form 4 filing.